5

15

20

CLAIMS

- 1. Use of a salt of L-ascorbic acid with a pharmaceutically acceptable organic base to prepare a pharmaceutical composition, for ophthalmic topical use, capable of improving the level of L-ascorbic acid in a human eye.
- 2. Use according to Claim 1, characterized in that the said organic base is chosen from the group comprising tromethamine, N-methyl-glucosamine, lysine, arginine and ornithine.
- 3. Use according to Claim 1, characterized in that the said organic base is tromethamine or lysine.
 - 4. Use according to any one of Claims 1 to 3, characterized in that the said composition is a cream or a sterile solution.
 - 5. Use according to any one of Claims 1 to 4, characterized in that the said composition comprises from 0.1 to 20 mg/ml of the said salt of L-ascorbic acid with a pharmaceutically acceptable organic base and at least one pharmaceutically acceptable inert vehicle.
 - 6. Use according to Claim 5, characterized in that the said composition comprises from 0.2 to 10 mg/ml of the said salt of L-ascorbic acid with a pharmaceutically acceptable organic base and at least one pharmaceutically acceptable inert vehicle.
 - 7. Use according to Claim 5, characterized in that the said composition comprises from 0.5 to 2 mg/ml of the said salt of L-ascorbic acid with a pharmaceutically acceptable organic base and at least one pharmaceutically acceptable inert vehicle.
- 8. Use according to any one of Claims 1 to 7, characterized in that the said composition is a sterile collyrium comprising a salt of L-ascorbic acid with lysine or with tromethamine.
 - 9. Use according to Claim 8, characterized in that the said composition also comprises an anti-inflammatory drug.
- 30 10. Use according to Claim 9, characterized in that the said

WO 03/077905 PCT/EP03/02258

- 11 -

anti-inflammatory drug is dexamethasone.

5

15

25

- 11. Therapeutic method for improving the level of L-ascorbic acid in a human eye, the said method comprising the topical administration to the said eye of a salt of L-ascorbic acid with a pharmaceutically acceptable organic base.
- 12. Method according to Claim 11, in which the said organic base is chosen from the group comprising tromethamine, N-methylglucosamine, lysine, arginine and ornithine.
- 13. Method according to Claim 11, in which the said organic base is 10 tromethamine or lysine.
 - 14. Method according to Claims 11 to 13, comprising the administration 1 to 24 times a day of a sterile pharmaceutical dosage form comprising from 0.1 to 20 mg/ml of the said salt.
 - 15. Method according to Claims 11 to 13, comprising the administration 3 to 12 times a day of a sterile pharmaceutical dosage form comprising from 0.1 to 20 mg/ml of the said salt.
 - 16. Method according to Claims 11 to 13, comprising the administration 1 to 24 times a day of a sterile pharmaceutical dosage form comprising from 0.2 to 10 mg/ml of the said salt.
- 20 17. Method according to Claims 11 to 13, comprising the administration 3 to 12 times a day of a sterile pharmaceutical dosage form comprising from 0.2 to 10 mg/ml of the said salt.
 - 18. Method according to Claims 11 to 13, comprising the administration 1 to 24 times a day of a sterile pharmaceutical dosage form comprising from 0.5 to 2 mg/ml of the said salt.
 - 19. Method according to Claims 11 to 13, comprising the administration 3 to 12 times a day of a sterile pharmaceutical dosage form comprising from 0.5 to 2 mg/ml of the said salt.
- 20. Method according to Claims 11 to 19, also comprising the ophthalmic topical administration of an anti-inflammatory. 30

WO 03/077905 PCT/EP03/02258

- 12 -

21. Method according to Claims 11 to 20, also comprising the ophthalmic topical administration of dexamethasone.